title: Association between the presence of anti-HLA antibodies with acute rejection and chronic allograft nephropathy in the first year after kidney transplantation.
abstract: The clinical relevance of anti-HLA antibodies following kidney transplantation has been a recent focus of research. Patients who present anti-HLA antibodies in the posttransplantation period have shown higher incidences of acute rejection episodes (ARE) and chronic allograft nephropathy (CAN). The objective of this study was to evaluate the presence of anti-HLA antibodies during the first year after kidney transplantation and their association with the occurrence of ARE and CAN. Eighty-eight kidney transplant recipients were evaluated for the presence of IgG anti-HLA antibodies using an enzyme-linked immunosorbent assay (LAT-M and LAT-1240, One Lambda Inc, Calif, United States). Protocol kidney biopsies were performed in consenting patients. ARE and CAN were diagnosed by clinical, laboratory, and histopathological criteria. Anti-HLA antibodies were observed in 20 (22.7%) patients. At 1 year follow-up, 26.1% presented ARE and 51.2% developed CAN. Nine patients (45%) with antibodies developed ARE as opposed to 20.6% without antibodies and 64.7% developed CAN as opposed to 47.8% of those without antibodies. In the histological analysis, the anti-HLA antibodies were associated with Banff IIA ARE (P = .001) and Banff grade II CAN (P = .012). Routine posttransplantation search for antibodies may identify cases at higher risk for acute and chronic rejection, and perhaps help to tailor the immunosuppressive regimen.
authors.affiliation: Immunology and Nephrology Divisions, Hospital de Clínicas de Porto Alegre and Graduate Programme in Medical Sciences: Nephrology - Universidade Federal do Rio Grande do Sul Medical School, Porto Alegre, RS, Brazil. rtoresan@hcpa.ufrgs.br
authors.forename: R
authors.initials: R
authors.lastname: Toresan
authors.forename: R C
authors.initials: RC
authors.lastname: Manfro
authors.forename: M C C
authors.initials: MC
authors.lastname: Proença
authors.forename: F J V
authors.initials: FJ
authors.lastname: Veronese
authors.forename: P H
authors.initials: PH
authors.lastname: Salim
authors.forename: D M
authors.initials: DM
authors.lastname: da Silva
authors.forename: A R
authors.initials: AR
authors.lastname: Ribeiro
authors.forename: M I A
authors.initials: MI
authors.lastname: Edelweiss
authors.forename: K L
authors.initials: KL
authors.lastname: Pegas
authors.forename: L F J
authors.initials: LF
authors.lastname: Jobim
mesh_terms: D000208:Acute Disease; D001323:Autoantibodies / Q000097:blood*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000097:blood / Q000276:immunology* / Q000473:pathology*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D001323:Autoantibodies; D006680:HLA Antigens